1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
  1. My Preqin
Book a demo

Emergence Therapeutics AG

Have updates for this profile?  Please contribute data

About Employee data
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2019

Location

Duisburg Germany

Primary Industry

Pharmaceuticals

About

Founded in 2019 and based in Duisburg, Germany, Emergence Therapeutics AG is a developer of novel antibody-drug conjugate immuno-therapeutics intended to treat cancer. The company uses ATAC technology to target Nectin-4 providing doctors and healthcare organizations with an effective drug as a therapy tool to treat cancer.
Current Investors
Idinvest Partners, NRW Bank, Kurma Partners

Request a demo to show more

Primary Industry
Pharmaceuticals
Sub Industries
Oncology/Cancer Treatment, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.emergencetx.com
Verticals
Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only

Employee Data

Employee Graph

Want to see the Employee Count?

Request a demo for full access to this profile.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo